US sign-up averts major EU crisis, but India, China actives still problematic
This article was originally published in Scrip
Executive Summary
New EU rules on importing Active Pharmaceutical Ingredients coming into force on 2 July may bring problems for European manufacturers and patients, industry sources are still warning. But the situation for companies could be better than feared because the major sources of APIs such as the US, India and China, have made it clear that they will, after all, comply with the EU regulation.